tert-butyl 4-[(4-nitrophenyl)acetyl]piperazine-1-carboxylate | 643087-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 4-[(4-nitrophenyl)acetyl]piperazine-1-carboxylate
• 英文别名: 1-Piperazinecarboxylic acid, 4-[(4-nitrophenyl)acetyl]-, 1,1-dimethylethylester；tert-butyl 4-[2-(4-nitrophenyl)acetyl]piperazine-1-carboxylate
• CAS: 643087-38-1
• 化学式: C₁₇H₂₃N₃O₅
• 分子量: 349.387
• InChiKey: HKAYXRLMYDVZQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  95.7
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 储存条件：
  应存放在室温、密封和干燥的环境中。

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[(4-nitrophenyl)acetyl]piperazine-1-carboxylate 在 sodium hydride 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors

  摘要：

  Truncation of potent and selective dibasic inhibitors afforded monocharged inhibitors of human mast-cell tryptase. Using two classes of analogues as lead structures, several monocharged derivatives were identified with Ki values ranging front 0.084 to 0.21 muM against the enzyme. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00444-9
• 作为产物：
  描述：

  对硝基苯乙酸 在 氯化亚砜 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl 4-[(4-nitrophenyl)acetyl]piperazine-1-carboxylate
  参考文献：
  名称：

  Monocharged inhibitors of mast cell tryptase derived from potent and selective dibasic inhibitors

  摘要：

  Truncation of potent and selective dibasic inhibitors afforded monocharged inhibitors of human mast-cell tryptase. Using two classes of analogues as lead structures, several monocharged derivatives were identified with Ki values ranging front 0.084 to 0.21 muM against the enzyme. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00444-9

文献信息

• Oxazolo[4,5-b]pyridine-Based Piperazinamides as GSK-3β Inhibitors with Potential for Attenuating Inflammation and Suppression of Pro-Inflammatory Mediators
  作者：Mushtaq A. Tantray、Imran Khan、Hinna Hamid、Mohammad Sarwar Alam、Abhijeet Dhulap、Ajaz Ahmad Ganai

  DOI：10.1002/ardp.201700022

  日期：2017.8

  Furthermore, these compounds (7d, 7e, 7g, and 7c) were also found to substantially inhibit pro‐inflammatory mediators, i.e., TNF‐α, IL‐1β, and IL‐6, ex vivo in comparison to indomethacin and did not pose any gastric ulceration risk, indicating the potential of this oxazolopyridine scaffold for the development of GSK‐3β inhibitors and their application as anti‐inflammatory agents.

  最近的研究表明，糖原合酶激酶-3β (GSK-3β) 是一种促炎酶，通过抑制这种激酶，可以控制炎症。在这方面，合成了一系列 17 种哌嗪连接的恶唑并 [4,5-b] 吡啶基衍生物，并评估了体外 GSK-3β 抑制和体内抗炎活性。在所有合成的化合物中，化合物 7d、7e、7g 和 7c 显示出最好的 GSK-3β 抑制活性，相应的 IC50 值为 0.34、0.39、0.47 和 0.53 µM。在大鼠足爪水肿模型中检测了化合物 7d、7e、7g 和 7c 的体内抗炎活性，化合物 7d 表现出最大的抑制作用，在角叉菜胶给药后 3 和 5 小时，爪体积分别减少 62.79% 和 65.91%分别与吲哚美辛相比（3 小时和 79 小时为 76.74%。角叉菜胶给药后 5 小时为 54%）。此外，与吲哚美辛相比，这些化合物（7d、7e、7g 和 7c）还被发现在体外显着抑制促炎介质，即 TNF-α、IL-1β
• Diaminopyrimidinecarboxa mide derivative
  申请人：Nagashima Shinya

  公开号：US20050272753A1

  公开（公告）日：2005-12-08

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗呼吸道疾病，特别是哮喘、慢性阻塞性肺病等与STAT 6有关的化合物。该化合物是一种嘧啶衍生物或其盐，其在2位具有可以被指定取代基取代的芳基氨基或芳基乙基氨基，4位具有被苄基基团或类似基团取代的氨基，5位具有可以被取代的氨基甲酰基。
• Diaminopyrimidinecarboxamide Derivative
  申请人：Nagashima Shinya

  公开号：US20090281072A1

  公开（公告）日：2009-11-12

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗呼吸系统疾病，特别是哮喘、慢性阻塞性肺疾病等与STAT 6有关的化合物。该化合物为嘧啶衍生物或其盐，其在2位具有可被取代的芳基氨基或芳基乙基氨基基团，4位具有氨基取代的苯甲基基团或类似基团，5位具有可被取代的氨基甲酰基团。
• DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE
  申请人：Nagashima Shinya

  公开号：US20110294749A1

  公开（公告）日：2011-12-01

  A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.

  提供了一种可用于预防或治疗涉及STAT 6的呼吸系统疾病，特别是哮喘、慢性阻塞性肺疾病等的化合物。该化合物为嘧啶衍生物或其盐，其在2位具有可以被指定取代基取代的芳基氨基或芳基乙基氨基基团，在4位具有可以被苄基或类似物取代的氨基基团，并在5位具有可以被取代的氨基甲酰基团。
• DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1518855B1

  公开（公告）日：2011-10-26